Well Care Compounding Pharmacy (Well Care Discount Pharmacy LLC), Las Vegas, NV

Is Well Care Compounding Pharmacy (Well Care Discount Pharmacy LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Well Care Compounding Pharmacy (Well Care Discount Pharmacy LLC) hold a Nevada pharmacy license?

State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002631 for WELL CARE DISCOUNT PHARMACY LLC, LAS VEGAS, NV, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001301 for Well Care Discount Pharmacy, LLC, Las Vegas, NV, status Expired, as of Nov 10, 2026.

Has Well Care Compounding Pharmacy (Well Care Discount Pharmacy LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Sep 17, 2020), 1 untitled letter (Jul 17, 2019), 1 state referral letter (Sep 17, 2020) and 1 FMD-145 letter (Sep 17, 2020) for Well Care Compounding Pharmacy (Well Care Discount Pharmacy LLC). State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Well Care Discount Pharmacy LLC; Well Care Compounding Pharmacy
Location
Las Vegas, NV
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 17, 2020
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 14 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Well Care Discount Pharmacy LLC, (dba Well Care Compounding Pharmacy), a 503A facility, with 4 dated actions.

Document
Sep 17, 2020Warning letter close-outWarning Letter Close Out Issued 09/17/2020Not linked by FDA
Sep 17, 2020State referral letterState Referral Letter Issued 09/17/2020Not linked by FDA
Sep 17, 2020FMD-145 letterFMD-145 Letter Issued 09/17/2020Not linked by FDA
Jul 17, 2019Untitled letterUntitled Letter Issued 07/17/2019fda.gov

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Well Care Discount Pharmacy, LLC, Las Vegas, NV (FEI number 3012289984), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 27, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30122899841058202
May 12, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3012289984967318

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending May 12, 2016 to Jun 27, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 25, 2018 to Jun 27, 2018: 3 observations

Firm on the cover
Well Care Discount Pharmacy, LLC, 3300 w. Charleston Blvd . , Suit e A, Las Vegas, NV 89102
FEI number
3012289984
Establishment type on the cover
Producer of Non- Sterile Drug Products
FDA district office on the cover
1 431 Harbor Bay Parkway Alameda, CA 94502- 7070
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Drug products failing to meet established specifications are not rejected.

Specifically,

Your firm failed to reject Testosterone 2mg/gram cream, lot 02092017:71@29 after you received potency testing results with a result of 126%, outside your range of <Redacted B4> This lot was distributed to <Redacted B4> patients and your pharmacist was unable to determine if the patients were notified of the superpotent drug product.

In addition, your firm does not routinely perform potency testing on your drug products and has not tested any drug products produced since August 2017.

Observation 2

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Specifically,

Observation 3

Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components used in the manufacture, processing, packing, or holding of drug products.

Specifically,

Your firm does not utilize compendia! grade purified water for the production of drug products. For example, your firm utilizes non-compendia! grade D) (<Redacted B4> water purchased from <Redacted B4> stores to use in the production of drug products including but not limited to Dyclonine 1 % Oral Solution as shown on the logged formula worksheet for lot #04202018:35@19 produced on 4/23/2018.

In addition, your firm has not performed any microbial testing on the store bought <Redac ted B4> water.

Inspection May 2, 2016 to May 12, 2016: 11 observations

Firm on the cover
Well Care Discount Pharmacy LLC DBA Well Care Compounding, 3430 E Tropicana Ave Ste 9, Las Vegas, NV
FEI number
3012289984
Establishment type on the cover
89121-7345 Producer of Sterile Drugs
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.

Specifically, A. Your firm has not performed smoke studies under dynamic conditions to demonstrate unidirectional air flow patterns in the REDACTED (B)(4) where sterile injectable drug products are prepared. According to the Lab Manager, smoke studies have been performed; however, your firm does not have any documented evidence of these studies.

B. The REDACTED (B)(4) has not been correctly performed for all batches of sterile injectable drugs ever produced at your firm. On 05/02/2016 and 05/04/2016, we observed the Lab Manager performing REDACTED (B)(4). The Lab Manager REDACTED (B)(4). He was unable to REDACTED (B)(4). Without REDACTED (B)(4), your firm lacks sterility assurance of sterile injectable drugs produced at your firm. Between 04/01/2014 and 05/10/2016, approximately REDACTED (B)(4) batches of sterile injectable drugs were prepared by your firm.

C. Your firm's Lab Manager was repeatedly observed performing sterile manipulations that blocked the HEPA un idirectional air flow. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient in that walls and ceilings are not smooth and/or hard surfaces that are easily cleanable.

Specifically, on 05/02/2016 and 05/04/2016, we observed the aseptic preparations of TESTOSTERONE CYP Lot# 04292016:35@11 and MEETHYLCOBALAMIN Lot# 05042016:98@11, respectively. During the production of these lots we observed the following:

A. We observed exposed wood-like material underneath the

REDACTED (B)(4) of the ISO 5 REDACTED (B)(4). The ISO 5 REDACTED (B)(4) made REDACTED (B)(4). Underneath the REDACTED (B)(4) we observed REDACTED (B)(4) that exposes the wood-like material. The REDACTED (B)(4). The wood-like material is particle shedding, difficult to clean and disinfect, and may harbor microbial contamination.

B. ln the ISO 8 clean room where the ISO 5 REDACTED (B)(4) is located, we observed a countertop/work bench and several storage shelving are made of laminated particle board. We observed exposed wood-like material on the underneath sides of the countertop/work bench and the shelving.

C. In addition, your firm's ISO 8 clean room ceiling is made of pop-up tiles. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The flow of components, drug product containers, closures, in-process materials, and drug products though the building is not designed to prevent contamination.

Specific ally, A. On 05/02/2016, we observed the aseptic preparation of TESTOSTERONE CYP Lot# 04292016:35@11. We observed the Lab Manager moving components and materials from the non-ISO classified area and also from ISO 8 room to the ISO 5 REDACTED (B)(4) without disinfecting them. The components and materials were pl aced REDACTED (B)(4

) without being wiped down with any disinfectant. On ce REDACTED (B)(4), t hey were only sprayed with sterile REDACTED (B)(4) . We noted not all component and material surfaces were exposed to the sterile REDACTED (B)(4).

B. We observed the Lab Manager used his bare hands to open the plastic curtains and entered the ISO 8 clean room head first. We observed Lab Manager's bare hands and facial skins touching the plastic curtains.

c. Weighing and mixing of non-sterile APIs and excipients for sterile preparations were not done in an ISO classified area. On 05/04/2016, we observed the aseptic preparation of METHYLCOBALAMIN Lot# 05042016:98@11. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, your firm does not adequately perform sterility and endotoxin testing on each lot of your firm's sterile products. Your firm's testing is inadequate for the following:

A. Your firm does not routinely perform sterility and endotoxin testing on your firm's sterile products. Since January 1, 2016, your firm has not performed endotoxin testing on any sterile products and performed sterility testing on REDACTED (B)(4) of sterile product. Your firm has produced REDACTED (B)(4) lots of sterile product during that time period. Also, the Lab Manager has explained that approximately REDACTED (B)(4) of sterile products produced before January 1st, 2016 were

B. A ccording to the REDACTED (B)(4) of sterility testing results from your contract testing laboratory, the sterility tests performed are not compliant to compendial standards because the "suitability of the method for the product has not been documented."

c. Your firm combines REDACTED (B)(4) to make a combination product. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, environmental monitoring operations are inadequate for the following:

A. Pressure differential (PD) of the clean room facility is not monitored. Your firm lacks documented evidence that the PD is monitored on each day a batch of sterile drug is prepared in the ISO 5. Also, your firm has no pressure gauge installed to monitor the PD between the ISO 8 clean room and the unclassified area.

B. Your firm's environmental and personnel monitoring are not performed each day that a batch of sterile drug is produced in the ISO 5 REDACTED (B)(4). Instead, they are performed on a REDACTED (B)(4) basis.

c. Your firm has no written description, or justifications for how each environmental monitoring location was determined.

D. Growth promotion was not performed for each lot of REDACTED (B)(4) for surface and gloved fingertip sampling.

E. Media suitable for the detection of yeast and mold species are not used in the environmental and personnel monitoring of your firm's clean room facility.

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. Non-sterile lint-free wipes and non-sterile disinfectants, specifically, non-sterile REDACTED (B)(4) and non-sterile REDACTED (B)(4) are used to clean your firm's clean room facility including the ISO 5 REDACTED (B)(4).

B.

C. On 05/04/2016, we observed your firm's Lab Manager performing REDACTED (B)(4) cleaning of the ISO 5 REDACTED (B)(4) using sterile REDACTED (B)(4) and non-sterile wipe. The Lab Manager indicated that he could not REDACTED (B)(4). In addition, we observed the Lab Manager cleaning the REDACTED (B)(4) with his upper body leaning REDACTED (B)(4). The Lab Manager wore non-sterile gown, non-sterile hair net, and non-sterile beard cover. The bare skin on his face was exposed.

D. On 05/02/2016, we observed reddish/orange spots on the REDACTED (B)(4) surface of the REDACTED (B)(4). Your firm's Lab Manager stated that the reddish/orange spots were probably spills from stopping or capping methylcobalamin (B12) vials

E. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

Specifically,

A. Your firm's has no justifications for assigning Beyond-Use Dates on the finish drug product beyond the expiration date of its ingredients. However, your firm routinely assigns Beyond-Use Dates that are longer than the expiration date of its ingredients. For example, the finish sterile product, ESTRADIOL VALERATE, Lot# 03092016:30@19 had a Beyond-Use Date of 06/07/2016. This lot was prepared using REDACTED (B)(4) which had an expiration date of 02/28/2016.

REDACTED (B)(4) lots reviewed of HCG Injection Solution which were produced in the last 6 months contained ingredients that expired before the finished product's Beyond-Use Date. REDACTED (B)(4) lots of Estradiol Valerate 10 mg/mL Injection Solution which were produced in the last 6 months contained ingredients that expired before the finished product's Beyond-Use Date.

B. Your firm's Beyond-Use Date testing program for your sterile products consists of REDACTED (B)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 8

Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure

that they are suitable for their intended use.

Specifically, glassware used in the mixing and heating of API for sterile drug processing is not adequately depyrogenated. We observed glassware was depyrogenated REDACTED (B)(4). Your firm's SOP 8.010, entitled "Sterilization and Depyrogenation", version 1.0, effective 08/26/2013, section 9.6.2 specifies REDACTED (B)(4) in order to achieve depyrogenation.

Observation 9

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your firm does not review any unexplained discrepancies or failures of any batches. For example:

A. Your firm has experienced failed batches due to REDACTED (B)(4) failures. The Lab Manager explained that the failures occur approximately REDACTED (B)(4). These batch failures were not investigated. The Lab Manager stated that the batch records were destroyed. However, there is no documented evidence showing that the batches were discarded.

B. On 05/02/2016 and 05/04/2016, we observed the aseptic preparations of TESTOSTERONE CYP Lot # 04292016:35@11 and METHYLCOBALAMIN Lot# 05042016:98@11. We observed a failure in the REDACTED (B)(4) during the production of sterile product. No investigation was performed on the failed REDACTED (B)(4).

Observation 10

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specifically, there is a lack of equipment/instruments calibration. For example, your firm has not calibrated the following equipment/instruments.

Pressure gauges for the ISO 5 REDACTED (B)(4) have never been calibrated.

REDACTED (B)(4) for the REDACTED (B)(4) have never been calibrated

Incubator used for the incubation of environmental monitoring (EM), personnel monitoring (PM), and media

Observation 11

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, the garments and protective apparel worn by your Lab Manager is inadequate. Your firm's clean room gowning consists of non-sterile shoe covers, non-sterile hair net, non-sterile face mask, non-sterile beard cover, non-sterile lab coat, and sterile gloves.

State board of pharmacy records

State board of pharmacy records for Nevada are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026 (it takes requests for discipline records); its license verification is an interactive search.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002631NONRESIDENT PHARMACYWELL CARE DISCOUNT PHARMACY LLCLAS VEGAS, NVINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001301Non Resident PharmacyWell Care Discount Pharmacy, LLCLas Vegas, NVExpired

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.